Angelini Pharma is an international pharmaceutical company focused on the research, development, and commercialization of health solutions with a preeminent focus on brain health, including mental health and epilepsy, and consumer healthcare.

Angelini Pharma

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment also provides breeding, propagation, and production/processing of seeds, including seed dressing. The company has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; and Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft was founded in 1863 and is headquartered in Leverkusen, Germany.

Friedrich Bayer

Johann Friedrich Weskott

Bayer Aktiengesellschaft

Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation, primarily investing in pioneering science that offers potential benefits for patients.

Boehringer Ingelheim Venture Fund

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

Metric
Company Name	Angelini Pharma	Bayer Aktiengesellschaft	Boehringer Ingelheim Venture Fund	GSK plc
Symbol		BAYN		GSK
MSH ID	COM:ANGELINIPHARMA	COM:BAYER	COM:BOEHRINGER-INGELHEIM-VENTURE	COM:GSK
Market	PRIVATE	STOCKS	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare	Financial Services & Finance	Healthcare
Industry	Pharmaceuticals	Drug Manufacturers - General	Venture Capital	Drug Manufacturers - General
Country	IT	DE	DE	GB
Stage
Employee Count		98.19K		70.21K
Website	angelinipharma.com	bayer.com	boehringer-ingelheim-venture.com	gsk.com
LinkedIn		bayer
Founders

Metric
Market Cap		27.44B	786.32M
Enterprise Value
Monthly Web Traffic	15.77K		1.33M
Web Traffic Growth	-0.39		0.02
Valuation
Raised Capital

Metric
Revenue	50.32B	38.64B
Revenue (LTM)
Revenue (NTM)
Gross Profit	29.46B	27.08B
EBITDA	13.04B	11.83B
Operating Income	8.88B	8.91B
Net Income	-3.11B	6.28B
EPS	-3.16	1.55
Diluted EPS	-3.16	1.53
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.59	0.73
Operating Profit Margin	0.08	0.26
EBITDA Margin	0.26	0.31
Net Profit Margin	-0.03	0.16
Return on Equity	-0.04	0.39
Return on Assets	-0.01	0.08
Return on Capital Employed	0.04	0.20

COM:ANGELINIPHARMA

Angelini Pharma

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-7.66	11.10
P/B Ratio	0.84	5.13
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	0.63	2.37
EV Multiple	-0.89	5.83

Metric
Days Sales Outstanding
Days Payables Outstanding	118.44	678.29
Days Inventory Outstanding	257.77	247.86
Operating Cycle	389.93	338.14
Cash Conversion Cycle	270.05	-264.26
Asset Turnover	0.39	0.54

Metric
Operating Cash Flow	4.29B	8.09B
Free Cash Flow	1.38B	5.10B
Cash Flow to Debt	0.16	0.42
Operating Cash Flow/Sales	0.16	0.24
Free Cash Flow Yield	-0.02	0.05

Metric
Cash & Equivalents	6.24B	3.74B
Accounts Receivable	727.74M	-826.97M
Inventory	14.73B	7.01B
Goodwill	34.12B	8.68B
Debt to Capitalization	0.57	0.56
Debt to Assets	0.41	0.34
Current Ratio	1.13	0.95
Quick Ratio	0.87	0.60

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue	0.12	0.20
SG&A to Revenue	0.05	0.31